triple-hormone-receptor agonist retatrutide for obesity 2023年度回顧】 NEJM Notable Articles of 2023 Day 3: Triple–Hormone-Receptor — A Phase 2 Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide | GLP-1R/GIPR/GCGR ligand |

Only 28.8% of participants exceeded 1 mg/week

Based on Phase 2 studies, the initial dose may begin at 1 mg to 2 mg (0.0750.15 mL) once weekly, with gradual titration every 4 weeks in increments of 2 mg to 4 mg, as tolerated, up to a maximum of 12 mg (0.90 mL) weekly Doses between 4 mg and 12 mg weekly demonstrated meaningful reductions in body weight and glycemic parameters over 16 to 28 weeks

We view the shortage of GLP-1s to be much worse than the official data suggests, said Cook, because the prices of these medications in the U.S

These cells are responsible for producing collagen, the structural protein that gives skin strength and resilience